Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00055562 · ClinicalTrials.gov registry record · Phase 2
Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects With Metastatic Malignant Melanoma
A Phase 2 study, sponsored by Celgene Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 274
- Enrollment target
NCT00055562 is a Phase 2 study that has completed, run by Celgene Corporation. The registered enrollment target is 274 participants.
The verdict
NCT00055562, a Phase 2 study, has completed, sponsored by Celgene Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 274 participants
- Enrollment target
Study Summary
Subjects are randomized to one of two treatment arms. All subjects are screened for eligibility within 28 days prior to randomization. The study consists of a treatment phase and a follow-up phase. Subjects will be treated in repeating 4 week cycles.
Interventions
- DRUG CC 5013
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 274 participants |
| Start Date | 2003-01 |
| Est. Completion | 2004-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00055562
The ClinicalTrials.gov registry entry for NCT00055562 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 274 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene Corporation, which has 40 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CC 5013 is the first listed.
NCT00055562 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00055562 about?
NCT00055562 is a clinical study titled "Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects With Metastatic Malignant Melanoma". Subjects are randomized to one of two treatment arms. All subjects are screened for eligibility within 28 days prior to randomization. The study consists of a treatment phase and a follow-up phase. Subjects will be treated in repeating 4 week cycles.
What is the current status of trial NCT00055562?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 274 participants. The study started on 2003-01. Estimated completion is 2004-12.
What interventions are being tested in trial NCT00055562?
The interventions under investigation include: CC 5013 (DRUG).
Who is sponsoring clinical trial NCT00055562?
This trial is sponsored by Celgene Corporation, which has 40 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.